Welcome to LookChem.com Sign In|Join Free

CAS

  • or

577-11-7

Post Buying Request

577-11-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

577-11-7 Usage

Chemical Properties

Different sources of media describe the Chemical Properties of 577-11-7 differently. You can refer to the following data:
1. white solid, often supplied as an aqueous solution
2. Docusate sodium is a white or almost white, waxlike, bitter tasting, plastic solid with a characteristic octanol-like odor. It is hygroscopic and usually available in the form of pellets, flakes, or rolls of tissuethin material.

Uses

Different sources of media describe the Uses of 577-11-7 differently. You can refer to the following data:
1. dioctyl sodium sulfosuccinate is a mild surfactant used as a cleans ing agent.
2. Dioctyl sulfosuccinate sodium salt is a wetting and emulsifying agent that is slowly soluble in water, having a solubility of 1 g in 70 ml of water. It functions as a wetting agent in fumaric acid-containing powdered fruit drinks to help the acid dissolve in water. It is used as a stabilizing agent on gums at not more than 0.5% by weight of the gum. It is used as a flavor potentiator in canned milk where it improves and maintains the flavor of the sterilized milk during storage. It also functions as a processing aid in the manufacture of unrefined sugar. It is also termed sodium dioctylsulfosuccinate.
3. Sodium salt of Docusate, used for the treatment of constipation, acting as a laxative or stool softener. Also used in the synthesis of electrospun fibres for tailored and controlled antibiotic drug release.
4. Forms reverse micelles in hydrocarbon solvents; Suitable for the solubilization of the major myelin transmembrane proteolipid
5. anticholinergic, treatment of motion sickness

Production Methods

Maleic anhydride is treated with 2-ethylhexanol to produce dioctyl maleate, which is then reacted with sodium bisulfite.

Brand name

Colace (Roberts Pharmaceutical); Correctol Stool Softener Laxative (Schering-Plough HealthCare); Dialose (Johnson & Johnson-Merck Consumer); Doxinate (Hoechst-Roussel); D-S-S (Parke-Davis); Modane Soft (Savage); Molofac (Bristol-Myers Squibb).

General Description

Odorless colorless to white waxy solid. Sinks and mixes slowly with water.

Air & Water Reactions

Mixes slowly with water.

Reactivity Profile

Docusate sodium causes foaming and spreading of water. Assists in putting out fires by water. [USCG, 1999].

Health Hazard

Liquid is strong irritant to eye and may irritate skin by removing natural oils. Ingestion causes diarrhea and intestinal bloating.

Fire Hazard

Behavior in Fire: Causes foaming and spreading of water. Assists in putting out fires by water.

Flammability and Explosibility

Nonflammable

Pharmaceutical Applications

Docusate sodium and docusate salts are widely used as anionic surfactants in pharmaceutical formulations. Docusate sodium is mainly used in capsule and direct-compression tablet formulations to assist in wetting and dissolution.

Safety Profile

Poison by intravenous route. Moderately toxic by ingestion and intraperitoneal routes. A skin and severe eye irritant. See also ESTERS. When heated to decomposition it emits toxic fumes of SOx and Na2O.

Safety

Docusate salts are used in oral formulations as therapeutic agents for their fecal softening and laxative properties. As a laxative in adults, up to 500mg of docusate sodium is administered daily in divided doses; in children over 6 months old, up to 75 mg in divided doses is used. The quantity of docusate sodium used as an excipient in oral formulations should therefore be controlled to avoid unintended laxative effects. Adverse effects associated with docusate sodium include diarrhea, nausea, vomiting, abdominal cramps, and skin rashes. As with the chronic use of laxatives, the excessive use of docusate sodium may produce hypomagnesemia. Docusate salts are absorbed from the gastrointestinal tract and excreted in bile; they may cause alteration of the gastrointestinal epithelium. The gastrointestinal or hepatic absorption of other drugs may also be affected by docusate salts, enhancing activity and possibly toxicity. Docusate sodium should not be administered with mineral oil as it may increase the absorption of the oil. LD50 (mouse, IV): 0.06 g/kg LD50 (mouse, oral): 2.64 g/kg LD50 (rat, IP): 0.59 g/kg LD50 (rat, oral): 1.9 g/kg

Solubility in organics

Dioctyl sodium sulfosuccinate (DSS) is the dioctyl ester of sodium sulfosuccinate (bis-2-ethyl-hexyl sodium sulfosuccinate). It dissolves slowly in water; at 25°C to the extent of 1.5 gm/100cc; at 70°C, 5.5 gm/100cc. It dissolves in oils, hydrocarbons, fats and waxs by heating above 75°C and remains in solution when cooled to room temperature. At room temperature, it is readily soluble in most organic solvents, both polar and non-polar. soluble in carbon tetrachloride, petroleum ether, naphtha, xylene, dibutyl phthalate, liquid petroleum, acetone, alcohol, vegetable oils.

storage

Docusate sodium is stable in the solid state when stored at room temperature. Dilute aqueous solutions of docusate sodium between pH 1–10 are stable at room temperature. However, at very low pH (<1) and very high pH (>10) docusate sodium solutions are subject to hydrolysis. The solid material is hygroscopic and should be stored in an airtight container in a cool, dry place.

Purification Methods

Dissolve it in MeOH and the inorganic salts which precipitate are filtered off. Water is added and the solution is extracted several times with hexane. The residue is evaporated to one-fifth its original volume, *benzene is added and azeotropic distillation is continued until no water remains. The solvent is evaporated. The white residual solid is crushed and dried in vacuo over P2O5 for 48hours [El Seoud & Fendler J Chem Soc, Faraday Trans 1 71 452 1975]. [Beilstein 4 IV 114.] It solubilises major myelin trans membrane proteolipids, and forms reverse micelles in hydrocarbon solvents.

Incompatibilities

Electrolytes, e.g. 3% sodium chloride, added to aqueous solutions of docusate sodium can cause turbidity. However, docusate sodium possesses greater tolerance to calcium, magnesium, and other polyvalent ions than do some other surfactants. Docusate sodium is incompatible with acids at pH < 1 and with alkalis at pH > 10.

Regulatory Status

GRAS listed. Included in the FDA Inactive Ingredients Database (IM injections; oral capsules, suspensions, and tablets; also topical formulations). Included in nonparenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients.

Check Digit Verification of cas no

The CAS Registry Mumber 577-11-7 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,7 and 7 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 577-11:
(5*5)+(4*7)+(3*7)+(2*1)+(1*1)=77
77 % 10 = 7
So 577-11-7 is a valid CAS Registry Number.
InChI:InChI=1/C20H38O7S.Na/c1-5-9-11-16(7-3)14-26-19(21)13-18(28(23,24)25)20(22)27-15-17(8-4)12-10-6-2;/h16-18H,5-15H2,1-4H3,(H,23,24,25);/q;+1

577-11-7 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (44203)  Dioctyl sulfosuccinate sodium salt, 96%   

  • 577-11-7

  • 100g

  • 300.0CNY

  • Detail
  • Alfa Aesar

  • (44203)  Dioctyl sulfosuccinate sodium salt, 96%   

  • 577-11-7

  • 500g

  • 1154.0CNY

  • Detail
  • Sigma-Aldrich

  • (Y0001567)  Docusatesodium  European Pharmacopoeia (EP) Reference Standard

  • 577-11-7

  • Y0001567

  • 1,880.19CNY

  • Detail
  • Aldrich

  • (323586)  Dioctylsulfosuccinatesodiumsalt  ≥97%

  • 577-11-7

  • 323586-5G

  • 325.26CNY

  • Detail
  • Aldrich

  • (323586)  Dioctylsulfosuccinatesodiumsalt  ≥97%

  • 577-11-7

  • 323586-25G

  • 446.94CNY

  • Detail
  • Aldrich

  • (323586)  Dioctylsulfosuccinatesodiumsalt  ≥97%

  • 577-11-7

  • 323586-100G

  • 776.88CNY

  • Detail
  • Aldrich

  • (323586)  Dioctylsulfosuccinatesodiumsalt  ≥97%

  • 577-11-7

  • 323586-500G

  • 2,614.95CNY

  • Detail
  • Aldrich

  • (323586)  Dioctylsulfosuccinatesodiumsalt  ≥97%

  • 577-11-7

  • 323586-1KG

  • 4,695.21CNY

  • Detail
  • Sigma-Aldrich

  • (86140)  Docusatesodiumsalt  purum, ≥96.0% (TLC)

  • 577-11-7

  • 86140-100G

  • 374.40CNY

  • Detail
  • Sigma-Aldrich

  • (86140)  Docusatesodiumsalt  purum, ≥96.0% (TLC)

  • 577-11-7

  • 86140-500G

  • 1,104.48CNY

  • Detail
  • Sigma-Aldrich

  • (86140)  Docusatesodiumsalt  purum, ≥96.0% (TLC)

  • 577-11-7

  • 86140-1KG

  • 1,440.27CNY

  • Detail

577-11-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name Docusate sodium

1.2 Other means of identification

Product number -
Other names sbo

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only. Finishing agents,Intermediates,Processing aids, not otherwise listed,Surface active agents
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:577-11-7 SDS

577-11-7Synthetic route

maleic anhydride
108-31-6

maleic anhydride

2-Ethylhexyl alcohol
104-76-7

2-Ethylhexyl alcohol

sodium docusate
577-11-7

sodium docusate

Conditions
ConditionsYield
Stage #1: maleic anhydride; 2-Ethylhexyl alcohol at 60 - 130℃; under 760.051 Torr; for 3.5h;
Stage #2: With sodium hydrogensulfite; sodium hydroxide In water at 107℃; for 1h; Reagent/catalyst; Temperature;
98.2%
bis(2-ethylhexyl) maleate

bis(2-ethylhexyl) maleate

sodium docusate
577-11-7

sodium docusate

Conditions
ConditionsYield
With sodium metabisulfite In ethanol for 10h; Temperature; Time; Inert atmosphere; Reflux;94%
2-(methoxycarbonylamino)-1H-benzimidazole-1-carboxylic acid

2-(methoxycarbonylamino)-1H-benzimidazole-1-carboxylic acid

A

sodium docusate
577-11-7

sodium docusate

B

sodium ligninsulfonate

sodium ligninsulfonate

cobalt bis(2-ethylhexyl) sulfosuccinate

cobalt bis(2-ethylhexyl) sulfosuccinate

sodium docusate
577-11-7

sodium docusate

Conditions
ConditionsYield
With sodium tetrahydroborate In ethanol; n-heptane
bis(2-ethylhexyl) maleate
142-16-5

bis(2-ethylhexyl) maleate

sodium docusate
577-11-7

sodium docusate

Conditions
ConditionsYield
With sodium disulfite In water at 104℃; for 3.16667h; Inert atmosphere;
choline chloride
67-48-1

choline chloride

sodium docusate
577-11-7

sodium docusate

choline dioctylsulfosuccinate
1214261-62-7

choline dioctylsulfosuccinate

Conditions
ConditionsYield
In water; acetone at 20℃;100%
procainamide hydrochloride
614-39-1

procainamide hydrochloride

sodium docusate
577-11-7

sodium docusate

procainamide docusate
1234189-07-1

procainamide docusate

Conditions
ConditionsYield
In water; acetone at 20℃;100%
sodium docusate
577-11-7

sodium docusate

tramadol hydrochloride

tramadol hydrochloride

tramadolium docusate

tramadolium docusate

Conditions
ConditionsYield
In water; acetone at 20℃;100%
(E)-1-(2-(3,7-dimethylocta-2,6-dienyloxy)-2-oxoethyl)-3-methyI-1H-imidazol-3-ium chloride
1234188-85-2

(E)-1-(2-(3,7-dimethylocta-2,6-dienyloxy)-2-oxoethyl)-3-methyI-1H-imidazol-3-ium chloride

sodium docusate
577-11-7

sodium docusate

(E)-1-(2-(3,7-dimethylocta-2,6-dienyloxy)-2-oxoethyl)-3-methyI-1H-imidazol-3-ium docusate
1234188-87-4

(E)-1-(2-(3,7-dimethylocta-2,6-dienyloxy)-2-oxoethyl)-3-methyI-1H-imidazol-3-ium docusate

Conditions
ConditionsYield
In water; acetone at 20℃;100%
sodium docusate
577-11-7

sodium docusate

rasagiline
136236-51-6

rasagiline

rasagiline docusate
1260684-42-1

rasagiline docusate

Conditions
ConditionsYield
Stage #1: sodium docusate With hydrogenchloride In dichloromethane; water
Stage #2: rasagiline In acetone for 2h; Product distribution / selectivity;
100%
sodium docusate
577-11-7

sodium docusate

phenergan
58-33-3

phenergan

promethazine docusate
1234189-02-6

promethazine docusate

Conditions
ConditionsYield
In water; acetone at 20℃;99%
2-(1H,1H,2H,2H-perfluorooctylthio)-1-methylimidazolium chloride

2-(1H,1H,2H,2H-perfluorooctylthio)-1-methylimidazolium chloride

sodium docusate
577-11-7

sodium docusate

2-(1H,1H,2H,2H-perfluorooctylthio)-1-methylimidazolium docusate

2-(1H,1H,2H,2H-perfluorooctylthio)-1-methylimidazolium docusate

Conditions
ConditionsYield
In acetone at 20℃;99%
acidine
590-46-5

acidine

sodium docusate
577-11-7

sodium docusate

betainium docusate

betainium docusate

Conditions
ConditionsYield
In ethanol at 25℃;99%
ephedrine hydrochloride
50-98-6

ephedrine hydrochloride

sodium docusate
577-11-7

sodium docusate

ephedrinium docusate
1234188-67-0

ephedrinium docusate

Conditions
ConditionsYield
In water; acetone at 20℃;98%
cabozantinib hydrochloride

cabozantinib hydrochloride

sodium docusate
577-11-7

sodium docusate

cabozantinib docusate

cabozantinib docusate

Conditions
ConditionsYield
In water; ethyl acetate at 20℃;98%
sodium docusate
577-11-7

sodium docusate

erlotinib hydrochloride
183319-69-9

erlotinib hydrochloride

erlotinib 1,4-bis(2-ethylhexoxy)-1 ,4-dioxobutane-2-sulfonate

erlotinib 1,4-bis(2-ethylhexoxy)-1 ,4-dioxobutane-2-sulfonate

Conditions
ConditionsYield
In dichloromethane; water at 20℃;98%
vardenafil hydrochloride

vardenafil hydrochloride

sodium docusate
577-11-7

sodium docusate

C23H32N6O4S*C20H38O7S

C23H32N6O4S*C20H38O7S

Conditions
ConditionsYield
In water; ethyl acetate for 4h;98%
sodium docusate
577-11-7

sodium docusate

3,3'-(octane-1,8-diyl)bis(1-methyl-1H-imidazolium) bromide

3,3'-(octane-1,8-diyl)bis(1-methyl-1H-imidazolium) bromide

1,8-bis(3-methylimidazolium-1-yl)octane docusate

1,8-bis(3-methylimidazolium-1-yl)octane docusate

Conditions
ConditionsYield
In water; acetone at 50℃; for 24h;98%
water
7732-18-5

water

sodium docusate
577-11-7

sodium docusate

copper(II) nitrate

copper(II) nitrate

copper(II) bis(2-ethylhexyl)sulfosuccinate tetrahydrate

copper(II) bis(2-ethylhexyl)sulfosuccinate tetrahydrate

Conditions
ConditionsYield
In diethyl ether byproducts: NaNO3; Na compd. completely dissolved in anhyd. ether at room temp.; soln. of Cu(NO3)2 in anhyd. ether added dropwise; stirred for 4 h; NaNO3 removed by supercentrifugation; solvent evapd. from soln.; dried under vac. at 338 K for 24 h; elem. anal.;97%
sodium docusate
577-11-7

sodium docusate

gefitinib
184475-35-2

gefitinib

gefitinib docusate

gefitinib docusate

Conditions
ConditionsYield
With hydrogenchloride In dichloromethane; water at 20℃; for 3.5h;97%
sildenafil hydrochloride
252920-86-8

sildenafil hydrochloride

sodium docusate
577-11-7

sodium docusate

C22H30N6O4S*C20H38O7S

C22H30N6O4S*C20H38O7S

Conditions
ConditionsYield
In water; ethyl acetate for 3h;97%
C53H112N2(2+)*2Br(1-)

C53H112N2(2+)*2Br(1-)

sodium docusate
577-11-7

sodium docusate

C53H112N2(2+)*2C20H37O7S(1-)

C53H112N2(2+)*2C20H37O7S(1-)

Conditions
ConditionsYield
In water; ethyl acetate at 20℃;97%
sodium docusate
577-11-7

sodium docusate

donepezil hydrochloride

donepezil hydrochloride

donepezil docusate

donepezil docusate

Conditions
ConditionsYield
In water at 20℃; for 4h;96.54%
ceritinib hydrochloride

ceritinib hydrochloride

sodium docusate
577-11-7

sodium docusate

ceritinib docusate

ceritinib docusate

Conditions
ConditionsYield
In water; ethyl acetate for 4h;96%
Gefitinib hydrochloride
184475-55-6

Gefitinib hydrochloride

sodium docusate
577-11-7

sodium docusate

gefitinib docusate

gefitinib docusate

Conditions
ConditionsYield
In dichloromethane; water at 20℃;96%
3-methyl-2-(3-methyl-5-phenyl-3H-benzooxazol-2-ylidenemethyl)benzothiazol-3-ium p-toluenesulfonate

3-methyl-2-(3-methyl-5-phenyl-3H-benzooxazol-2-ylidenemethyl)benzothiazol-3-ium p-toluenesulfonate

sodium docusate
577-11-7

sodium docusate

C23H19N2OS(1+)*C20H37O7S(1-)

C23H19N2OS(1+)*C20H37O7S(1-)

Conditions
ConditionsYield
In dichloromethane; water at 20℃; for 12h;96%
N,N-dibenzyl-N,N-tetraethylhexane-1,6-diaminium bromide

N,N-dibenzyl-N,N-tetraethylhexane-1,6-diaminium bromide

sodium docusate
577-11-7

sodium docusate

2C20H37O7S(1-)*C28H46N2(2+)

2C20H37O7S(1-)*C28H46N2(2+)

Conditions
ConditionsYield
In water; ethyl acetate at 20℃;96%
sodium docusate
577-11-7

sodium docusate

bis(2-ethylhexyl) sulfosuccinate
10041-19-7

bis(2-ethylhexyl) sulfosuccinate

Conditions
ConditionsYield
With hydrogenchloride In isopropyl alcohol at 70℃; for 3h;95.4%
With phosphoric acid In ethanol for 2h;
With hydrogenchloride In tetrahydrofuran; methanol at 0℃;
With hydrogenchloride In water at 20℃;
tetrabutylammomium bromide
1643-19-2

tetrabutylammomium bromide

sodium docusate
577-11-7

sodium docusate

tetrabutylammonium docusate

tetrabutylammonium docusate

Conditions
ConditionsYield
In water94%
1-tributyl-(2-hydroxyethyl)phosphonium chloride
54580-84-6

1-tributyl-(2-hydroxyethyl)phosphonium chloride

sodium docusate
577-11-7

sodium docusate

tri-n-butyl(2-hydroxyethyl)phosphonium docusate
1234189-12-8

tri-n-butyl(2-hydroxyethyl)phosphonium docusate

Conditions
ConditionsYield
In water; acetone at 20℃;92%
In water; acetone at 20℃;92%
1,3,3-Trimethyl-2-methyleneindoline
118-12-7

1,3,3-Trimethyl-2-methyleneindoline

ehyl 2-[N-ethoxyformyl methyl-N-(4-formylphenyl)]amino acetate
27919-79-5

ehyl 2-[N-ethoxyformyl methyl-N-(4-formylphenyl)]amino acetate

sodium docusate
577-11-7

sodium docusate

C27H33N2O4(1+)*C20H37O7S(1-)

C27H33N2O4(1+)*C20H37O7S(1-)

Conditions
ConditionsYield
Stage #1: 1,3,3-Trimethyl-2-methyleneindoline; ethyl 2-[N-ethoxyformyl methyl-N-(4-formylphenyl)]aminoacetate With acetic anhydride; acetic acid at 80℃; for 3h;
Stage #2: sodium docusate In ethyl acetate
92%
sodium docusate
577-11-7

sodium docusate

N-dodecylbetainium chloride
55142-08-0

N-dodecylbetainium chloride

C16H34NO2(1+)*C20H37O7S(1-)

C16H34NO2(1+)*C20H37O7S(1-)

Conditions
ConditionsYield
In ethanol at 25℃;92%
thiabendazole hydrochloride
945-65-3

thiabendazole hydrochloride

sodium docusate
577-11-7

sodium docusate

thiabendazolium docusate
1337932-57-6

thiabendazolium docusate

Conditions
ConditionsYield
In water; acetone at 20℃;91%

577-11-7Downstream Products

577-11-7Relevant articles and documents

Dual catalytic activity of amberlyst-15 in the large-scale and sustainable synthesis of dioctyl sodium sulfosuccinate (DOSS)

Fateh, Davod S.,Moghadam, Seyed M. M.,Salehi, Samie,Tarin, Mojtaba

, p. 555 - 559 (2020/07/17)

Dioctyl sodium sulfosuccinate (DOSS) as a unique material both as a drug and surfactant was synthesized by a facile and economical synthetic method. In this project, Amberlyst-15 was select-ed as a heterogeneous recyclable bronsted solid acid for this synthesis both in the esterification of ma-leic anhydride and sulfonation of dioctyl maleate (DOM) ester. This catalyst was easily recovered and reused at least for 13 consecutive cycles without a significant loss in the catalytic activity. In this paper, we wish to uncover a catalytic approach for the synthesis of DOSS through a recyclable, easily recov-erable, and commercially available catalyst, namely Amberlyst 15, under mild conditions.

Salts of alkyl esters of sulfonated dicarboxylic acids and compositions containing same

-

Page/Page column 4, (2011/08/03)

A salt of a mono- and/or dialkyl ester of a sulfonated dicarboxylic acid is provided, where the dicarboxylic acid contains 4 to 8 carbon atoms and the alkyl groups are derived from 2-propylheptanol. A composition including (a) one or more salt(s) of a mono- and/or dialkyl ester(s) of a sulfonated dicarboxylic acid(s), where the dicarboxylic acid contains 4 to 8 carbon atoms and the alkyl groups are derived from 2-propylheptanol; and (b) one or more organic solvents liquid at 20° C. with a boiling point above 250° C. at 1 bar is also provided.

Stable emulsion and process for preparing the same

-

, (2010/12/26)

The invention relates to a stable emulsion comprising (a) an oil; (b) water; (c) a surfactant; and (d) solid particulate material, wherein an emulsion comprising the oil, water, and the surfactant has a transitional phase inversion point, wherein the stable emulsion contains droplets having a d50 value of below 1 μm, and wherein the shelf life time of an emulsion comprising compounds (a) to (d) is longer than the shelf life time of emulsions containing only compounds (a) to (c).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 577-11-7